Álvaro Hidalgo-Vega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Álvaro Hidalgo-Vega has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
- María Merino
Health Outcomes Research Department, Weber, Madrid, Spain
10 shared publications - Juan Oliva-Moreno
Department of Economic Analysis and Finance, University of Castilla-La Mancha, Toledo, Spain
7 shared publications - Néboa Zozaya
Department of Health Economics, Weber, Madrid, Spain
7 shared publications - Renata Villoro
Weber Foundation, Majadahonda, Madrid, Spain,
5 shared publications P. Jaén
4 shared publications- Isaac Aranda-Reneo
Economic Analysis and Finance Department, Faculty of Social Science and Information Technologies, University of Castilla-La Mancha, Castilla-La Mancha, Spain
3 shared publications
Latest Publications
- 4 February 2026
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 101 (4)
Estudio Glaucoinnova: reflexión estratégica sobre la innovación en glaucoma en Andalucía
- 4 February 2026
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 101 (4)
Estudio Glaucoinnova: reflexión estratégica sobre la innovación en glaucoma en Andalucía
- 1 January 2026
- Published by Fundacion Weber
Atlas de la migraña en España: del diagnóstico a la acción
- 1 January 2026
- Published by Fundacion Weber
Atlas de la migraña en España: del diagnóstico a la acción
- Open Access
- 29 January 2025
- Published by Asociacion Didactica Andalucia in Journal of Sport and Health Research
- Vol. 17 (1) , 31-40
FACTORES SOCIOECONÓMICOS COMO PREDICTORES DE LA ACTIVIDAD FÍSICA, EL CONSUMO DE TABACO Y ALCOHOL, EN LA POBLACIÓN ADULTA ESPAÑOLA.
Objectives; in Spain, tobacco causes more than 50,000 deaths per (13% of annual deaths). More than 10,000 deaths were alcohol-attributable during 2016. Regular physical activity helps prevent and treat a number of noncommunicable diseases, as well as hypertension, overweight and obesity. It can also improve mental health, quality of life and well-being. The objectives of this study were to estimate the prevalence of these three lifestyle habits (3LH) in the adult Spanish population, as well as their relationship with individual socioeconomic factors. Methods; we used the European Health Interview Survey in Spain 2020, a population-based survey (n=21,569), to analyze the prevalence and relationship of the 3LH with the following socioeconomic factors: sex, age, nationality, cohabitation, education, social class and autonomous region of residence. Logistic regression models were used to calculate odds ratios, for each of the 3LH. Results; 78.6% of interviewees declared not to smoke and 34.5% not to drink alcohol. 14.1% of respondents reported to do exercise regularly (several times per week). Sex, age, nationality, cohabitation, education and social class had statistically significant effects (p<0.05) in the three models. Conclusions; this study provides evidence of the statistical association in Spanish adult population of the analyzed predictors with physical activity, tobacco and alcohol consumption. This information would be useful for designing prevention and treatment health policies that target the groups at risk.
- 29 January 2025
- Published by Asociacion Didactica Andalucia in Journal of Sport and Health Research
- Vol. 17 (1) , 31-40
Open AccessFACTORES SOCIOECONÓMICOS COMO PREDICTORES DE LA ACTIVIDAD FÍSICA, EL CONSUMO DE TABACO Y ALCOHOL, EN LA POBLACIÓN ADULTA ESPAÑOLA.
Objectives; in Spain, tobacco causes more than 50,000 deaths per (13% of annual deaths). More than 10,000 deaths were alcohol-attributable during 2016. Regular physical activity helps prevent and treat a number of noncommunicable diseases, as well as hypertension, overweight and obesity. It can also improve mental health, quality of life and well-being. The objectives of this study were to estimate the prevalence of these three lifestyle habits (3LH) in the adult Spanish population, as well as their relationship with individual socioeconomic factors. Methods; we used the European Health Interview Survey in Spain 2020, a population-based survey (n=21,569), to analyze the prevalence and relationship of the 3LH with the following socioeconomic factors: sex, age, nationality, cohabitation, education, social class and autonomous region of residence. Logistic regression models were used to calculate odds ratios, for each of the 3LH. Results; 78.6% of interviewees declared not to smoke and 34.5% not to drink alcohol. 14.1% of respondents reported to do exercise regularly (several times per week). Sex, age, nationality, cohabitation, education and social class had statistically significant effects (p<0.05) in the three models. Conclusions; this study provides evidence of the statistical association in Spanish adult population of the analyzed predictors with physical activity, tobacco and alcohol consumption. This information would be useful for designing prevention and treatment health policies that target the groups at risk.
- 12 January 2024
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 22 (3) , 297-313
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
Objectives The aim of this study was to review the current evaluation and funding processes for new drugs in different developed countries, to provide a comparative framework with detailed, homogeneous, and up-to-date information. Methods Scientific publications, reports and websites were reviewed between July and December 2021 using PubMed, Google Scholar, and grey literature sources. The main items searched were actors and processes, including timelines, characteristics of clinical and economic evaluations, participation of stakeholders, elements of price and reimbursement decisions, cost-effectiveness thresholds and specific funds. The analysed 13 countries were Australia, Canada, England, France, Germany, Italy, Japan, the Netherlands, Portugal, Scotland, South Korea, Spain and Sweden. Results Eight countries perform the assessment process separated from the pricing decision. Countries measure each drug’s added therapeutic value through multi-attribute value scales, algorithms, non-prescriptive lists of criteria, or quality-adjusted life years (QALYs). Health technology assessment (HTA) methodologies differ in their outcome measures, elicitation techniques, comparators, and perspectives. The criteria used for pricing and reimbursement include humanistic, clinical, and economic aspects. Only Scotland, England, the Netherlands, Canada and Portugal use explicit efficiency thresholds. Health care professionals participate in all assessment committees, and patients are becoming increasingly involved in most countries. The official time from marketing authorisation to the completion of the evaluation and pricing processes varied from 126 to 540 days. Conclusions Most analysed countries show a trend towards value-based approaches that consider value for money to society, but also other economic, clinical, and humanistic criteria. Good practices included robustness, transparency, independence, and participation.
- 12 January 2024
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 22 (3) , 297-313
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
Objectives The aim of this study was to review the current evaluation and funding processes for new drugs in different developed countries, to provide a comparative framework with detailed, homogeneous, and up-to-date information. Methods Scientific publications, reports and websites were reviewed between July and December 2021 using PubMed, Google Scholar, and grey literature sources. The main items searched were actors and processes, including timelines, characteristics of clinical and economic evaluations, participation of stakeholders, elements of price and reimbursement decisions, cost-effectiveness thresholds and specific funds. The analysed 13 countries were Australia, Canada, England, France, Germany, Italy, Japan, the Netherlands, Portugal, Scotland, South Korea, Spain and Sweden. Results Eight countries perform the assessment process separated from the pricing decision. Countries measure each drug’s added therapeutic value through multi-attribute value scales, algorithms, non-prescriptive lists of criteria, or quality-adjusted life years (QALYs). Health technology assessment (HTA) methodologies differ in their outcome measures, elicitation techniques, comparators, and perspectives. The criteria used for pricing and reimbursement include humanistic, clinical, and economic aspects. Only Scotland, England, the Netherlands, Canada and Portugal use explicit efficiency thresholds. Health care professionals participate in all assessment committees, and patients are becoming increasingly involved in most countries. The official time from marketing authorisation to the completion of the evaluation and pricing processes varied from 126 to 540 days. Conclusions Most analysed countries show a trend towards value-based approaches that consider value for money to society, but also other economic, clinical, and humanistic criteria. Good practices included robustness, transparency, independence, and participation.
- Open Access
- 1 June 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 1431-1442
A Social Return on Investment Analysis of Improving the Management of Chronic Obstructive Pulmonary Disease Within the Spanish National Healthcare System
Purpose: To define a set of proposals that would improve the current management of chronic obstructive pulmonary disease (COPD) within the Spanish National Healthcare System (SNHS) from a comprehensive multidisciplinary perspective and to assess the impact of its implementation from clinical, healthcare, economic, and social perspectives. Patients and Methods: A group of 20 stakeholders related to COPD (healthcare professionals, patients, and informal caregivers, among others) participated in an online Delphi process to agree on a set of 15 proposals that would improve the current management of COPD within the SNHS in four areas: diagnosis, risk stratification, management of exacerbations, and management of stable COPD. A one-year forecast-type social return on investment (SROI) analysis was used to estimate the impact that implementing the set of proposals would have in relation to the investment required. A sensitivity analysis was used to test the strength of the model when varying assumption-based data-points. Results: The hypothetical implementation of the complete set of 15 proposals would require a € 668 million investment and would generate a € 2079 million social impact concerning savings for the SNHS and quality of life improvements for patients and their informal caregivers, among others. Accordingly, for every euro invested in the set of proposals, a social return of € 3.11 would be generated (€ 2.71 in the worst-case scenario and € 3.62 in the best-case scenario) of both tangible (32.56%) and intangible nature (67.44%). Conclusion: Altogether, implementing this set of 15 proposals would generate a positive social impact, threefold the required investment. The results may inform decisions relative to healthcare policy and practice regarding COPD management within the SNHS, further contributing to reduce the large burden of COPD.
- 1 June 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 1431-1442
Open AccessA Social Return on Investment Analysis of Improving the Management of Chronic Obstructive Pulmonary Disease Within the Spanish National Healthcare System
Purpose: To define a set of proposals that would improve the current management of chronic obstructive pulmonary disease (COPD) within the Spanish National Healthcare System (SNHS) from a comprehensive multidisciplinary perspective and to assess the impact of its implementation from clinical, healthcare, economic, and social perspectives. Patients and Methods: A group of 20 stakeholders related to COPD (healthcare professionals, patients, and informal caregivers, among others) participated in an online Delphi process to agree on a set of 15 proposals that would improve the current management of COPD within the SNHS in four areas: diagnosis, risk stratification, management of exacerbations, and management of stable COPD. A one-year forecast-type social return on investment (SROI) analysis was used to estimate the impact that implementing the set of proposals would have in relation to the investment required. A sensitivity analysis was used to test the strength of the model when varying assumption-based data-points. Results: The hypothetical implementation of the complete set of 15 proposals would require a € 668 million investment and would generate a € 2079 million social impact concerning savings for the SNHS and quality of life improvements for patients and their informal caregivers, among others. Accordingly, for every euro invested in the set of proposals, a social return of € 3.11 would be generated (€ 2.71 in the worst-case scenario and € 3.62 in the best-case scenario) of both tangible (32.56%) and intangible nature (67.44%). Conclusion: Altogether, implementing this set of 15 proposals would generate a positive social impact, threefold the required investment. The results may inform decisions relative to healthcare policy and practice regarding COPD management within the SNHS, further contributing to reduce the large burden of COPD.
- Open Access
- 26 January 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-10
The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis
Haemophilia A (HA) has been associated with poor health-related quality of life and a large economic burden, accentuated by severity, arthropathy, and inhibitors. To meet global standards of care, the management of HA should align with the principles of care outlined by the World Federation of Haemophilia. The aims of the present study were to establish a set of proposals to improve HA management within the Spanish National Health System (SNHS) and to estimate the impact its hypothetical implementation would generate from a clinical, healthcare, economic, and social perspective. A multidisciplinary group of experts agreed on a set of 15 proposals to improve HA management within the SNHS. Thereafter, a forecast-type Social Return on Investment analysis was carried out to estimate the impact of implementing this set of proposals within the SNHS over a one-year timeframe, in relation to the required investment. This study estimated that the implementation of the complete set of 15 proposals would require a total investment of 2.34 M€ and have a total impact of 14.60 M€. Accordingly, every euro invested in the complete set of 15 proposals would yield a social return of €6.23 (€3.37 in the worst-case scenario and €9.69 in the best-case scenario) of both tangible and intangible nature in similar proportions (45.71 and 54.29%, respectively). These results can be used to inform policy and practice such that interventions that may potentially improve current public health challenges associated with the management of HA may be implemented.
- 26 January 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-10
Open AccessThe impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis
Haemophilia A (HA) has been associated with poor health-related quality of life and a large economic burden, accentuated by severity, arthropathy, and inhibitors. To meet global standards of care, the management of HA should align with the principles of care outlined by the World Federation of Haemophilia. The aims of the present study were to establish a set of proposals to improve HA management within the Spanish National Health System (SNHS) and to estimate the impact its hypothetical implementation would generate from a clinical, healthcare, economic, and social perspective. A multidisciplinary group of experts agreed on a set of 15 proposals to improve HA management within the SNHS. Thereafter, a forecast-type Social Return on Investment analysis was carried out to estimate the impact of implementing this set of proposals within the SNHS over a one-year timeframe, in relation to the required investment. This study estimated that the implementation of the complete set of 15 proposals would require a total investment of 2.34 M€ and have a total impact of 14.60 M€. Accordingly, every euro invested in the complete set of 15 proposals would yield a social return of €6.23 (€3.37 in the worst-case scenario and €9.69 in the best-case scenario) of both tangible and intangible nature in similar proportions (45.71 and 54.29%, respectively). These results can be used to inform policy and practice such that interventions that may potentially improve current public health challenges associated with the management of HA may be implemented.
- Open Access
- 8 January 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (6) , 968-980
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
CAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer. However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders. The experts identified three great challenges for implementing advanced therapies in Spain: therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.
- 8 January 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (6) , 968-980
Open AccessA strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
CAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer. However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders. The experts identified three great challenges for implementing advanced therapies in Spain: therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.
- 5 February 2020
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 16 (2) , e2080
A cost‐effectiveness analysis of robotic versus laparoscopic distal pancreatectomy
Aim: There is no study in the literature that evaluates the cost‐effectiveness of robotic distal pancreatectomy (RDP) over laparoscopic distal pancreatectomy (LDP). We performed a comparative study of RDP and LDP with the aim of evaluating clinical and cost‐effective outcomes.Material and Methods: This is an observational, comparative prospective nonrandomized study. The primary end point was to compare the cost‐effectiveness differences between both groups. A willingness to pay of €20 000 and €30 000 per quality‐adjusted life year (QALY) was used as a threshold to recognize which treatment was most cost‐effective.Results: A total of 31 RDP and 28 LDP have been included. The overall mean total cost was similar in both groups (RDP: €9712.15 versus LDP: €9424.68; P > .5). Mean QALYs for RDP (0.652) was higher than that associated with LDP (0.59) (P > .5).Conclusion: This study seems to provide data of cost‐effectiveness between RDP and LDP approaches, showing some benefits for RDP.
- 5 February 2020
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 16 (2) , e2080
A cost‐effectiveness analysis of robotic versus laparoscopic distal pancreatectomy
Aim: There is no study in the literature that evaluates the cost‐effectiveness of robotic distal pancreatectomy (RDP) over laparoscopic distal pancreatectomy (LDP). We performed a comparative study of RDP and LDP with the aim of evaluating clinical and cost‐effective outcomes.Material and Methods: This is an observational, comparative prospective nonrandomized study. The primary end point was to compare the cost‐effectiveness differences between both groups. A willingness to pay of €20 000 and €30 000 per quality‐adjusted life year (QALY) was used as a threshold to recognize which treatment was most cost‐effective.Results: A total of 31 RDP and 28 LDP have been included. The overall mean total cost was similar in both groups (RDP: €9712.15 versus LDP: €9424.68; P > .5). Mean QALYs for RDP (0.652) was higher than that associated with LDP (0.59) (P > .5).Conclusion: This study seems to provide data of cost‐effectiveness between RDP and LDP approaches, showing some benefits for RDP.
- Open Access
- 4 February 2020
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-16
Social value of a set of proposals for the ideal approach of multiple sclerosis within the Spanish National Health System: a social return on investment study
Background: Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disease that in many cases produces disability, having a high impact in patients’ lives, reducing significantly their quality of life. The aim of this study was to agree on a set of proposals to improve the current management of MS within the Spanish National Health System (SNHS) and apply the Social Return on Investment (SROI) method to measure the potential social impact these proposals would create. Methods: A Multidisciplinary Working Team of nine experts, with representation from the main stakeholders regarding MS, was set up to agree on a set of proposals to improve the management of MS. A forecast SROI analysis was carried out, with a one-year timeframe. Data sources included an expert consultation, a narrative literature review and a survey to 532 MS patients. We estimated the required investment of a hypothetical implementation, as well as the potential social value that it could create. We calculated outcomes in monetary units and we measured intangible outcomes through financial proxies. Results: The proposed ideal approach revealed that there are still unmet needs related to MS that can be addressed within the SNHS. Investment would amount to 148 million € and social return to 272 million €, so each euro invested could yield almost €2 of social return. Conclusions: This study could guide health interventions, resulting in money savings for the SNHS and increases in patients’ quality of life.
- 4 February 2020
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-16
Open AccessSocial value of a set of proposals for the ideal approach of multiple sclerosis within the Spanish National Health System: a social return on investment study
Background: Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disease that in many cases produces disability, having a high impact in patients’ lives, reducing significantly their quality of life. The aim of this study was to agree on a set of proposals to improve the current management of MS within the Spanish National Health System (SNHS) and apply the Social Return on Investment (SROI) method to measure the potential social impact these proposals would create. Methods: A Multidisciplinary Working Team of nine experts, with representation from the main stakeholders regarding MS, was set up to agree on a set of proposals to improve the management of MS. A forecast SROI analysis was carried out, with a one-year timeframe. Data sources included an expert consultation, a narrative literature review and a survey to 532 MS patients. We estimated the required investment of a hypothetical implementation, as well as the potential social value that it could create. We calculated outcomes in monetary units and we measured intangible outcomes through financial proxies. Results: The proposed ideal approach revealed that there are still unmet needs related to MS that can be addressed within the SNHS. Investment would amount to 148 million € and social return to 272 million €, so each euro invested could yield almost €2 of social return. Conclusions: This study could guide health interventions, resulting in money savings for the SNHS and increases in patients’ quality of life.
- 4 February 2020
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 24 (3) , 247-254
Robotic versus laparoscopic surgery for rectal cancer: a comparative cost-effectiveness study
The differences between the costs of robotic rectal resection and of the laparoscopic approach are still not well known. The aim of this study was to evaluate the cost-effectiveness of robotic versus laparoscopic surgery.
- 4 February 2020
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 24 (3) , 247-254
Robotic versus laparoscopic surgery for rectal cancer: a comparative cost-effectiveness study
The differences between the costs of robotic rectal resection and of the laparoscopic approach are still not well known. The aim of this study was to evaluate the cost-effectiveness of robotic versus laparoscopic surgery.